1GG5

CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN NAD[P]H-QUINONE OXIDOREDUCTASE AND A CHEMOTHERAPEUTIC DRUG (E09) AT 2.5 A RESOLUTION


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.279 
  • R-Value Work: 0.200 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones.

Faig, M.Bianchet, M.A.Winski, S.Hargreaves, R.Moody, C.J.Hudnott, A.R.Ross, D.Amzel, L.M.

(2001) Structure 9: 659-667

  • Primary Citation of Related Structures:  1H66, 1H69

  • PubMed Abstract: 
  • NAD(P)H:quinone acceptor oxidoreductase (QR1) protects animal cells from the deleterious and carcinogenic effects of quinones and other electrophiles. Remarkably, the same enzyme activates cancer prodrugs that become cytotoxic only after two-electron ...

    NAD(P)H:quinone acceptor oxidoreductase (QR1) protects animal cells from the deleterious and carcinogenic effects of quinones and other electrophiles. Remarkably, the same enzyme activates cancer prodrugs that become cytotoxic only after two-electron reduction. QR1's ability to bioactivate quinones and its elevated expression in many human solid tumors makes this protein an excellent target for enzyme-directed drug development. Until now, structural analysis of the mode of binding of chemotherapeutic compounds to QR1 was based on model building using the structures of complexes with simple substrates; no structure of complexes of QR1 with chemotherapeutic prodrugs had been reported.


    Related Citations: 
    • Crystal Structure of Human Quinone Reductase Type 2, a Metalloprotein
      Foster, C.,Bianchet, M.A.,Talalay, P.,Zhao, Q.,Amzel, L.M.
      (1999) Biochemistry 38: 9881
    • Structure and Mechanism of Cytosolic Quinone Reductases
      Bianchet, M.A.,Foster, C.,Faig, M.,Talalay, P.,Amzel, L.M.
      (1999) BIOCHEM.SOC.TRANS. 27: 610
    • Structures of Recombinant Human and Mouse Nad(P)H:Quinone Oxidoreductases: Species Comparison and Structural Changes with Substrate Binding and Release
      Faig, M.,Bianchet, M.A.,Talalay, P.,Chen, S.,Winski, S.,Ross, D.,Amzel, L.M.
      (2000) Proc.Natl.Acad.Sci.USA 97: 3177
    • The Three-Dimensional Structure of Nad(P)H:Quinone Reductase, a Flavoprotein Involved in Cancer Chemoprotection and Chemotherapy: Mechanism of Two-Electron Reduction
      Li, R.,Bianchet, M.A.,Talalay, P.,Amzel, L.M.
      (1995) Proc.Natl.Acad.Sci.USA 92: 8846


    Organizational Affiliation

    Department of Biophysics and Biophysical Chemistry, Johns Hopkins Medical School, Baltimore, MD 21205, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
NAD(P)H DEHYDROGENASE [QUINONE] 1
A, B, C, D
273Homo sapiensGene Names: NQO1 (DIA4, NMOR1)
EC: 1.6.5.2
Find proteins for P15559 (Homo sapiens)
Go to Gene View: NQO1
Go to UniProtKB:  P15559
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
FAD
Query on FAD

Download SDF File 
Download CCD File 
A, B, C, D
FLAVIN-ADENINE DINUCLEOTIDE
C27 H33 N9 O15 P2
VWWQXMAJTJZDQX-UYBVJOGSSA-N
 Ligand Interaction
E09
Query on E09

Download SDF File 
Download CCD File 
A, B, C, D
3-HYDROXYMETHYL-5-AZIRIDINYL-1METHYL-2-[1H-INDOLE-4,7-DIONE]-PROPANOL
C15 H18 N2 O4
JCCDRCRHGKFTQS-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.279 
  • R-Value Work: 0.200 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 56.733α = 76.42
b = 55.454β = 77.22
c = 97.205γ = 86.45
Software Package:
Software NamePurpose
DENZOdata reduction
CCP4data scaling
CNSrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2001-09-12
    Type: Initial release
  • Version 1.1: 2008-04-26
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2014-11-12
    Type: Structure summary